Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Franck Duclos is active.

Publication


Featured researches published by Franck Duclos.


Nature Genetics | 1995

β–sarcoglycan: characterization and role in limb–girdle muscular dystrophy linked to 4q12

Leland E. Lim; Franck Duclos; Odile Broux; Nathalie Bourg; Yoshihide Sunada; Valérie Allamand; Jon Meyer; Isabelle Richard; Carolyn R. Moomaw; Clive Slaughter; F. M. S. Tome; Michel Fardeau; Charles E. Jackson; Jacques S. Beckmann; Kevin P. Campbell

β–sarcoglycan, a 43 kDa dystrophin–associated glycoprotein, is an integral component of the dystrophin–glycoprotein complex. We have cloned human β–sarcoglycan cDNA and mapped the β–sarcoglycan gene to chromosome 4q12. Pericentromeric markers and an intragenic polymorphic CA repeat cosegregated perfectly with autosomal recessive limb–girdle muscular dystrophy in several Amish families. A Thr–to–Arg missense mutation was identified within the β–sarcoglycan gene that leads to a dramatically reduced expression of β–sarcoglycan in the sarcolemma and a concomitant loss of adhalin and 35 DAG, which may represent a disruption of a functional subcomplex within the dystrophin–glycoprotein complex. Thus, the β–sarcoglycan gene is the fifth locus identified (LGMD2E) that is involved in autosomal recessive limb–girdle muscular dystrophy.


Nature Genetics | 1995

Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12.

Leland E. Lim; Franck Duclos; Odile Broux; Nathalie Bourg; Yoshihide Sunada; Allamand; Jon Meyer; Isabelle Richard; Carolyn R. Moomaw; Clive A. Slaughter

β–sarcoglycan, a 43 kDa dystrophin–associated glycoprotein, is an integral component of the dystrophin–glycoprotein complex. We have cloned human β–sarcoglycan cDNA and mapped the β–sarcoglycan gene to chromosome 4q12. Pericentromeric markers and an intragenic polymorphic CA repeat cosegregated perfectly with autosomal recessive limb–girdle muscular dystrophy in several Amish families. A Thr–to–Arg missense mutation was identified within the β–sarcoglycan gene that leads to a dramatically reduced expression of β–sarcoglycan in the sarcolemma and a concomitant loss of adhalin and 35 DAG, which may represent a disruption of a functional subcomplex within the dystrophin–glycoprotein complex. Thus, the β–sarcoglycan gene is the fifth locus identified (LGMD2E) that is involved in autosomal recessive limb–girdle muscular dystrophy.


Journal of Biological Chemistry | 2009

Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE

Steve Poirier; Gaétan Mayer; Viviane Poupon; Peter S. McPherson; Roxane Desjardins; Kévin Ly; Marie-Claude Asselin; Robert W. Day; Franck Duclos; Mark R. Witmer; Rex A. Parker; Annik Prat; Nabil G. Seidah

Elevated levels of plasma low density lipoprotein (LDL)-cholesterol, leading to familial hypercholesterolemia, are enhanced by mutations in at least three major genes, the LDL receptor (LDLR), its ligand apolipoprotein B, and the proprotein convertase PCSK9. Single point mutations in PCSK9 are associated with either hyper- or hypocholesterolemia. Accordingly, PCSK9 is an attractive target for treatment of dyslipidemia. PCSK9 binds the epidermal growth factor domain A (EGF-A) of the LDLR and directs it to endosomes/lysosomes for destruction. Although the mechanism by which PCSK9 regulates LDLR degradation is not fully resolved, it seems to involve both intracellular and extracellular pathways. Here, we show that clathrin light chain small interfering RNAs that block intracellular trafficking from the trans-Golgi network to lysosomes rapidly increased LDLR levels within HepG2 cells in a PCSK9-dependent fashion without affecting the ability of exogenous PCSK9 to enhance LDLR degradation. In contrast, blocking the extracellular LDLR endocytosis/degradation pathway by a 4-, 6-, or 24-h incubation of cells with Dynasore or an EGF-AB peptide or by knockdown of endogenous autosomal recessive hypercholesterolemia did not significantly affect LDLR levels. The present data from HepG2 cells and mouse primary hepatocytes favor a model whereby depending on the dose and/or incubation period, endogenous PCSK9 enhances the degradation of the LDLR both extra- and intracellularly. Therefore, targeting either pathway, or both, would be an effective method to reduce PCSK9 activity in the treatment of hypercholesterolemia and coronary heart disease.


Molecular Cell | 1998

Functional Rescue of the Sarcoglycan Complex in the BIO 14.6 Hamster Using δ-Sarcoglycan Gene Transfer

Kathleen H. Holt; Leland E. Lim; Volker Straub; David Venzke; Franck Duclos; Richard D. Anderson; Beverly L. Davidson; Kevin P. Campbell

Four types of limb-girdle muscular dystrophy (LGMD) are known to be caused by mutations in distinct sarcoglycan genes. The BIO 14.6 hamster is a model for sarcoglycan-deficient LGMD with a deletion in the delta-sarcoglycan (delta-SG) gene. We investigated the function of the sarcoglycan complex and the feasibility of sarcoglycan gene transfer for LGMD using a recombinant delta-SG adenovirus in the BIO 14.6 hamster. We demonstrate extensive long-term expression of delta-sarcoglycan and rescue of the entire sarcoglycan complex, as well as restored stable association of alpha-dystroglycan with the sarcolemma. Importantly, muscle fibers expressing delta-sarcoglycan lack morphological markers of muscular dystrophy and exhibit restored plasma membrane integrity. In summary, the sarcoglycan complex is requisite for the maintenance of sarcolemmal integrity, and primary mutations in individual sarcoglycan components can be corrected in vivo.


American Journal of Pathology | 1998

Molecular Pathogenesis of Muscle Degeneration in the δ-Sarcoglycan-Deficient Hamster

Volker Straub; Franck Duclos; David Venzke; Jane C. Lee; Susan Cutshall; Cynthia J. Leveille; Kevin P. Campbell

The BIO14.6 hamster is an extensively used animal model of autosomal recessive cardiomyopathy and muscular dystrophy. Recently, a large deletion in the 5′ end of the δ-sarcoglycan gene was found to be the primary genetic defect in the hamster. In the present investigation, we studied the effects of the δ-sarcoglycan deletion on transcription, expression, and function of the dystrophin-glycoprotein complex in skeletal and cardiac muscle. We demonstrated that in striated muscle the genetic defect leads to the complete deficiency of δ-sarcoglycan and a concomitant loss of α-, β-, and γ-sarcoglycan. In addition, absence of the sarcoglycan complex reduced the expression of α-dystroglycan in striated muscle fibers. These findings indicated that the primary defect in the BIO14.6 hamster leads to the dissociation of the dystroglycan complex from the sarcoglycan complex and disrupted anchorage of α-dystroglycan to the cell surface. Using intravenous injection of Evans blue dye as an in vivo tracer assay, we demonstrated that perturbation of the dystrophin-glycoprotein complex caused extensive fiber damage in skeletal and cardiac muscle of the BIO14.6 hamster. Based on our results, we propose that loss of δ-sarcoglycan results in the impairment of sarcolemmal integrity, finally leading to muscular dystrophy and cardiomyopathy.


Journal of Biological Chemistry | 1996

Characterization of δ-sarcoglycan, a novel component of the oligomeric sarcoglycan complex involved in limb-girdle muscular dystrophy

Daniel Jung; Franck Duclos; Barbara L. Apostol; Volker Straub; Jane C. Lee; Valérie Allamand; David Venzke; Yoshihide Sunada; Carolyn R. Moomaw; Cynthia J. Leveille; Clive A. Slaughter; Thomas O. Crawford; John D. McPherson; Kevin P. Campbell

The sarcoglycan complex is known to be involved in limb-girdle muscular dystrophy (LGMD) and is composed of at least three proteins: α-, β-, and γ-sarcoglycan. δ-Sarcoglycan has now been identified as a second 35-kDa sarcolemmal transmembrane glycoprotein that shares high homology with γ-sarcoglycan and is expressed mainly in skeletal and cardiac muscle. Biochemical analysis has demonstrated that γ- and δ-sarcoglycan are separate entities within the sarcoglycan complex and that all four sarcoglycans exist in the complex on a stoichiometrically equal basis. Immunohistochemical analysis of skeletal muscle biopsies from patients with LGMD2C, LGMD2D, and LGMD2E demonstrated a reduction of the entire sarcoglycan complex in these muscular dystrophies. Furthermore, we have mapped the human δ-sarcoglycan gene to chromosome 5q33-q34 in a region overlapping the recently linked autosomal recessive LGMD2F locus.


FEBS Letters | 1996

Absence of γ-sarcoglycan (35 DAG) in autosomal recessive muscular dystrophy linked to chromosome 13q12

Daniel Jung; Yoshihide Sunada; Franck Duclos; Fernando M.S. Tomé; Carolyn R. Moomaw; Luciano Merlini; K. Azibi; M. Chaouch; Clive A. Slaughter; Michel Fardeau; Jean Claude Kaplan; Kevin P. Campbell

We have partially sequenced rabbit skeletal muscle γ‐sarcoglycan an integral component of the dystrophin‐glycoprotein complex. Specific antibodies were produced against a γ‐sarcoglycan peptide and used to examine the expression of γ‐sarcoglycan in skeletal muscle of patients with severe childhood autosomal muscular dystrophy linked to chromosome 13q12 (SCARMD). We show by immunofluorescence and Western blotting that in skeletal muscle from these patients γ‐sarcoglycan is completely absent and α‐ and β‐sarcoglycan are greatly reduced in abundance, whereas other components of the DGC are preserved. In addition, we show that in normal muscle α‐, β‐, and γ‐sarcoglycan constitute a tightly associated sarcolemma complex which can not be disrupted by SDS treatment.


Neuromuscular Disorders | 1998

β-Sarcoglycan: genomic analysis and identification of a novel missense mutation in the LGMD2E Amish isolate

Franck Duclos; Odile Broux; Nathalie Bourg; Volker Straub; G.L Feldman; Yoshihide Sunada; Leland E. Lim; F. Piccolo; S Cutshall; F Gary; F Quetier; Jean-Claude Kaplan; Charles E. Jackson; Jacques S. Beckmann; Kevin P. Campbell

The sarcoglycan complex is involved in the etiology of four autosomal recessive limb-girdle muscular dystrophies (LGMD2C-F). A missense mutation (T151R) in the beta-sarcoglycan gene on chromosome 4q12 has been shown to cause a mild form of LGMD2E in 11 families from a Southern Indiana Amish community sharing a common haplotype. We now report that two sibs from another Amish family with mild LGMD2E are compound heterozygotes for chromosome 4q12 markers. In order to characterize the genetic defect in this new family, we determined the genomic organization of the beta-sarcoglycan gene. A second missense mutation (R91C) has now been identified in this LGMD2E Amish family. This mutation is also present in the homozygous state in another family of probable Amish ancestry. Finally, analysis of all the components of the dystrophin-glycoprotein complex was performed for the first time on a biopsy from a patient homozygous for the beta-sarcoglycan mutation (T151R). Interestingly, in addition to the loss of the entire sarcoglycan complex, we detected a reduction of alpha-dystroglycan which suggests a role for the sarcoglycan complex in stabilizing alpha-dystroglycan at the sarcolemma.


Journal of Biological Chemistry | 2010

Effects of the Prosegment and pH on the Activity of PCSK9 EVIDENCE FOR ADDITIONAL PROCESSING EVENTS

Suzanne Benjannet; Yascara Grisel Luna Saavedra; Josée Hamelin; Marie-Claude Asselin; Rachid Essalmani; Antonella Pasquato; Peter Lemaire; Gerald J. Duke; Bowman Miao; Franck Duclos; Rex A. Parker; Gaétan Mayer; Nabil G. Seidah

PCSK9, a target for the treatment of dyslipidemia, enhances the degradation of the LDL receptor (LDLR) in endosomes/lysosomes, up-regulating LDL-cholesterol levels. Whereas the targeting and degradation of the PCSK9-LDLR complex are under scrutiny, the roles of the N- and C-terminal domains of PCSK9 are unknown. Although autocatalytic zymogen processing of PCSK9 occurs at Gln152↓, here we show that human PCSK9 can be further cleaved in its N-terminal prosegment at Arg46↓ by an endogenous enzyme of insect High Five cells and by a cellular mammalian protease, yielding an ∼4-fold enhanced activity. Removal of the prosegment acidic stretch resulted in ∼3-fold higher binding to LDLR in vitro, in ≥4-fold increased activity on cellular LDLR, and faster cellular internalization in endosome/lysosome-like compartments. Finally, swapping the acidic stretch of PCSK9 with a similar one found in the glycosylphosphatidylinositol-anchored heparin-binding protein 1 does not impair PCSK9 autoprocessing, secretion, or activity and confirmed that the acidic stretch acts as an inhibitor of PCSK9 function. We also show that upon short exposure to pH values 6.5 to 5.5, an ∼2.5-fold increase in PCSK9 activity on total and cell surface LDLR occurs, and PCSK9 undergoes a second cleavage at Arg248, generating a two-chain PCSK9-ΔN248. At pH values below 5.5, PCSK9 dissociates from its prosegment and loses its activity. This pH-dependent activation of PCSK9 represents a novel pathway to further activate PCSK9 in acidic endosomes. These data enhance our understanding of the functional role of the acidic prosegment and on the effect of pH in the regulation of PCSK9 activity.


Neuromuscular Disorders | 1996

Identification of muscle-specific calpain and β-sarcoglycan genes in progressive autosomal recessive muscular dystrophies

Jacques S. Beckmann; Isabelle Richard; Odile Broux; Françoise Fougerousse; Nathalie Bourg; L. Brenguier; Valérie Allamand; Nuchanard Chiannilkulchai; Carinne Roudaut; Franck Duclos; Leland E. Lim; Yoshihide Sunada; Jon Meyer; Carolyn R. Moomaw; Clive A. Slaughter; Fernando M.S. Tomé; Charles E. Jackson; Michel Fardeau; Kevin P. Campbell

The autosomal recessive forms of limb-girdle muscular dystrophies are encoded by at least five distinct genes. The work performed towards the identification of two of these is summarized in this report. This success illustrates the growing importance of genetics in modern nosology.

Collaboration


Dive into the Franck Duclos's collaboration.

Top Co-Authors

Avatar

Kevin P. Campbell

Roy J. and Lucille A. Carver College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Leland E. Lim

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar

Carolyn R. Moomaw

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

Odile Broux

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

Clive A. Slaughter

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nathalie Bourg

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

David Venzke

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar

Jon Meyer

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge